Wang Shengdian, Jia Mingming
CAS Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Datun Road #15, Chaoyang District, 100101, Beijing, China.
Adv Exp Med Biol. 2016;909:1-67. doi: 10.1007/978-94-017-7555-7_1.
Antibody-based immunotherapy has become a standard treatment for a variety of cancers. Many well-developed antibodies disrupt signaling of various growth factor receptors for the treatment of a number of cancers by targeting surface antigens expressed on tumor cells. In recent years, a new family of antibodies is currently emerging in the clinic, which target immune cells rather than cancer cells. These immune-targeted therapies strive to augment antitumor immune responses by antagonizing immunosuppressive pathways or providing exogenous immune-activating stimuli, which have achieved dramatic results in several cancers. The future of cancer therapies is likely to combine these approaches with other treatments, including conventional therapies, to generate more effective treatments.
基于抗体的免疫疗法已成为多种癌症的标准治疗方法。许多成熟的抗体通过靶向肿瘤细胞上表达的表面抗原，破坏各种生长因子受体的信号传导，从而治疗多种癌症。近年来，一类新的抗体正在临床中崭露头角，这类抗体靶向免疫细胞而非癌细胞。这些免疫靶向疗法致力于通过拮抗免疫抑制途径或提供外源性免疫激活刺激来增强抗肿瘤免疫反应，已在多种癌症中取得了显著成效。癌症治疗的未来可能会将这些方法与其他治疗方法（包括传统疗法）相结合，以产生更有效的治疗方案。
